The purpose of this study is to showcase advances in molecular imaging of atheroma biology in living individuals.
INTRODUCTION
Atherosclerosis is a chronic, systemic inflammatory disease characterized by the accumulation of lipids and inflammatory cells within the artery wall [1] . In the earliest stages, atherosclerosis primarily affects the intima; however, ongoing inflammation impacts deeper layers. Leaky neovessels penetrate from the adventitia, promoting atheroma expansion associated with plaque vulnerability [2] . Inflammation weakens the protective fibrous cap, which can lead to plaque rupture, responsible for most acute coronary syndromes. Therefore, inflammation and neovascularization are closely interrelated and serve as key imaging and therapeutic targets to stratify high and low-risk atheroma in vivo [3] .
Strategies to identify inflammation and neovascularization in human atheroma rely on biologyspecific, high-resolution imaging approaches. Conventional imaging can visualize structural plaque features (e.g. calcium, lipid deposits) and the degree of vessel stenosis [4] . Increasingly, molecular imaging approaches that complement structural data are unravelling key biology central to plaque stability [5] . In this review, we highlight exciting recent advances in atherosclerosis molecular and structural imaging of inflammation and neovascularization and its relationship to plaque pathobiology.
Hyperglycemia
Elevated serum glucose competitively decreases cellular FDG uptake, thus limiting application of FDG-PET in patients with uncontrolled diabetes mellitus, a common and high-risk atherosclerosis population. Data from 195 cardiovascular disease patients demonstrated that a prescan glucose level more than 7.0 mmol/l (126 mg/dl) inversely associated with carotid and aortic wall FDG uptake [9 & ], suggesting that FDG-PET imaging should be avoided in hyperglycemia.
Longer timepoint before FDG-PET imaging Delayed FDG imaging beyond the traditional 90 min timepoint might increase FDG bioavailability and reduce background FDG blood pool. In two studies, delaying FDG-PET imaging to 2.5-3 h after injection significantly increased the FDG plaque SUV and TBR signal [9 & ,10], a simple and effective strategy to improve plaque signal-to-noise. 18 
F-fluorodeoxyglucose-PET: secondary plaque inflammation readouts
Linking arterial and visceral organ inflammation Carotid and aortic plaque FDG activity in 173 obese patients was found to correlate significantly with FDG uptake in adipose tissue by multivariate regression analysis [11 & ]. Furthermore, increasing body weight associated with greater FDG signal in fat. Increased FDG metabolic activity in the spleen, a putative organ source of leukocytes and pro-inflammatory cytokines that can accelerate atherosclerosis, was associated with greater plaque FDG inflammation in 22 acute coronary syndrome patients [12 && ]. Remarkably, in a separate arm of this study including 464 individuals without known cardiovascular disease, splenic FDG uptake independently associated with future cardiovascular events (hazard ratio 3.3; 95% confidence interval 1.5-7.3; P ¼ 0.003) over a median 4-year follow-up period (Fig. 1 ). The concept of targeting systemic inflammation to reduce cardiovascular events is currently being tested in multiple large clinical trials [e.g. Cardiovascular Inflammation Reduction Trial (CIRT); Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)].
18

F-fluorodeoxyglucose-PET: assessment of novel plaque anti-inflammatory therapeutics
In 38 patients with familial hypercholesterolemia, arterial FDG activity modestly correlated with baseline LDL (R ¼ 0.37; P ¼ 0.03) [13 & ]. Following lipoprotein apheresis (>50% LDL reduction), FDG uptake significantly diminished within only 3 days, implicating high circulating lipoprotein levels as important direct mediators of chronic plaque inflammation.
In contrast, a multicentre trial of 72 atherosclerosis patients on low-dose statin therapy administered a new p38 mitogen-activated protein kinase (MAPK) inhibitor (BMS-582949) showed similar FDG plaque uptake to patients receiving placebo [14] . As a positive control, intensification of statin therapy significantly lowered plaque FDG inflammation. These findings suggest that BMS-582949 may not be a clinically efficacious anti-inflammatory therapy for atherosclerosis. Similarly, an anti-inflammatory 5-lipoxygenase inhibitor (VIA-2291) that blocks leukotriene synthesis [15] , an oxidized LDL neutralizing antibody (MLDL1278A) to inhibit immune complex formation [16 & ], and an Lp-PLA2 inhibitor (rilapladib) that decreases bioactive inflammatory mediators [17 & ], all failed to meet the primary endpoints to reduce arterial FDG plaque inflammatory activity. These studies highlight the potential predictive value of FDG plaque imaging in Phase I/II, which could have implications for streamlining phase III trials.
KEY POINTS
High-risk atherosclerotic plaques are characterized by chronic inflammation and leaky neovessels.
Molecular and structural imaging of neovascularization and inflammation are important diagnostic and therapeutic plaque imaging targets.
FDG-PET/CT remains a leading strategy for plaque inflammation imaging in human clinical studies.
Other imaging modalities including SPECT, MRI, optical, ultrasound and MRI for high-risk plaque imaging are available.
New imaging agents for molecular detection of plaque inflammation and neovascularization continue to be developed.
F-fluorodeoxyglucose-PET: advances in PET coronary artery imaging
Diet modulation
Coronary FDG-PET plaque imaging is limited by high background from the adjacent metabolically active myocardium. A randomized trial recently demonstrated that a high-fat, low-carbohydrate meal, followed by 12-h fast, reliably suppressed myocardial FDG uptake in most individuals [18 & ]. Quality of suppression was inversely linked to circulating free fatty acid levels, which may help select patients likely to provide high-quality noninvasive FDG-PET images of coronary arteries.
Intravascular imaging. To improve spatial resolution, intravascular nuclear scintillating balloon catheter imaging system prototypes have been engineered [19 & ,20 ]. The 1-2 mm resolution is a significant advance over the typical 3-5 mm resolution of noninvasive PET, although it remains to be seen whether intravascular PET will be a practical option for clinical investigation. exhibiting 35% greater radiotracer uptake in rabbit atheroma. The utility of FDM beyond or complementary to FDG is under investigation.
F-sodium fluoride PET imaging
In a major step forward in clinical molecular imaging, NaF-PET, actively used in oncology to assess cancer bone metastases, was applied to detect osteogenic activity in human coronary atheroma in vivo. NaF has minimal myocardial background compared with FDG, and therefore enables high-quality coronary PET images with good signal-to-noise. In a prospective 40-patient study with myocardial infarction or stable angina, NaF coronary plaque uptake localized to the culprit lesion in 93% of cases (TBR: 1.66 culprit vs. 1.24 nonculprit; P < 0.0001), and was associated with high-risk structural plaque features on intravascular ultrasound (Fig. 2) [22 && ]. In comparison, FDG plaque activity was not significantly different in culprit or nonculprit plaques, likely due to signal contamination from myocardial background. Prospective studies assessing NaF signal with clinical events are underway. It remains unclear whether NaF will provide predictive value beyond coronary artery calcium scores; however, NaF may detect a biologically more active process.
Combined inflammation and neovascularization PET imaging
Inflammation and neovascularization have been evaluated together with PET/CT via 18 F-Galacto-RGD, which targets the integrin avb3 cell membrane receptors expressed on both activated endothelial cells and inflammatory macrophages in atheroma. In 10 patients with carotid stenosis planned for endarterectomy, 18 F-Galacto-RGD uptake was significantly enhanced in regions of severe stenosis compared with less stenotic zones ( Fig. 3 ) and revealed a strong relationship with avb3 integrin expression on ex-vivo analysis (R ¼ 0.73,
]. Although correlations of 18 F-Galacto-RGD with macrophages (CD68 immunostaining; R ¼ 0.37) and microvessel density (CD-31 immunostaining; R ¼ 0.48) were less robust, and a difference between symptomatic and asymptomatic carotid plaques could not be demonstrated in this small study, investigations in larger numbers of high-risk atheroma patients are warranted. New translatable PET agents with improved binding affinity to enhance avb3 integrin detection, such as 64 Cu-DOTA-3-4A based on a labelled cysteine knot peptide [24] , and in-vivo albumin radiolabelling techniques to identify leaky neovasculature [25] , are also being developed preclinically.
SINGLE PHOTON EMISSION COMPUTERIZED TOMOGRAPHY
Single photon emission computerized tomography (SPECT) imaging offers lower resolution than PET (10 vs. 5 mm), but similar high-sensitivity reporting. Typically, SPECT employs 99m Tc, a radioisotope that possesses a short blood half-life and low absorbed radiation dose, and provides good signal-to-noise in vivo.
Interleukin-2 receptor imaging
In 10 symptomatic carotid stenosis patients, a 99m Tc-labelled interleukin-2 (IL-2) reporter ( 99m Tc-HYNIC-IL-2) that targets upregulated IL-2 receptor expression on plaque T-lymphocytes, was well tolerated, readily detectable in vivo and localized specifically on ex-vivo analysis [26] .
Folate receptor-b imaging
Human carotid endarterectomy specimens incubated with 99m Tc-folate, directed at the folate receptor-b, suggested that 99m Tc-folate detects the reparative (M2-like) subpopulation of plaque macrophages [27 & ], a property shared by targeted FDM-PET imaging [21 && ]. Folate-targeted receptors have been previously reported for clinical optical fluorescence detection [28] , and are also being developed for PET [29] . Validation of specific leukocyte molecular imaging markers beyond global macrophages may highlight a deeper understanding of in-vivo plaque pathobiology.
Leukocyte trafficking
SPECT imaging has also been utilized to track leukocyte homing to inflamed plaques in vivo. After baseline MRI and FDG-PET/CT characterization of carotid plaque, 10 cardiovascular disease patients were administered 99m Tc-labelled autologous peripheral blood mononuclear cells (PBMCs) followed by serial in-vivo SPECT/CT imaging over 6 h [30 & ]. Compared with healthy controls, 99m Tc-PBMC uptake was greater in diseased arteries (TBR 2.1 vs. 1.5; P ¼ 0.04). Importantly, 99m Tc-PBMC showed a strong correlation (R ¼ 0.88; P < 0.001) with FDG-PET metabolic activity, implying that already inflamed plaques preferentially recruit leukocytes ( Fig. 4) . Through improved understanding of leukocyte migration from organ reservoirs, new therapies designed to mitigate inflammatory enhancement of atheroma, such as targeted delivery of plaque-stabilizing payloads coupled to labelled leukocytes, may be realized. 
Vascular cell adhesion molecule-1
In a preclinical study, a 99m Tc-labelled single domain antibody fragment ( 99m Tc-cAbVCAM1-5) specific to VCAM-1, a surface receptor expressed on inflamed endothelium, revealed enhanced invivo uptake in murine atheroma [31] . 99m Tc-cAbV-CAM1-5 plaque uptake associated with histological VCAM-1 expression, and decreased in response to atorvastatin treatment. Single domain antibodylabelled agents such as 99m Tc-cAbVCAM1-5 represent new molecular imaging compounds that retain antibody sensitivity and specificity in a smaller package, and can be functionalized with reporters for multiple imaging platforms, and humanized for translation.
MRI
Dynamic contrast-enhancement
Dynamic contrast-enhancement (DCE)-MRI is a structural imaging modality that determines the extent and permeability of plaque neovasculature via the transfer coefficient K trans , which represents movement of gadolinium into the extracellular space. In an intriguing noninvasive study assessing both neovascularization and inflammation, 32 carotid stenosis patients underwent DCE-MRI and FDG-PET/CT to measure K trans and TBR, respectively [32 && ]. In histologically confirmed regions of high plaque inflammation and microvessels, multivariate regression modelling identified a significant link between plaque K trans and TBR (b ¼ 2.63; P < 0.0001) that was independent of the severity of anatomic stenosis or the presence of clinical symptoms. However, a separate 41-individual imaging-only study showed a strong association only in symptomatic carotid stenosis patients [33 & ], indicating that larger sample sizes may be needed to overcome patient and plaque diversity. This work provides confirmation that plaque inflammation and neovascularization are highly intertwined in vivo and identifies a potential population of vulnerable plaques for future outcomes studies.
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ULTRASOUND IMAGING
Vascular ultrasound is a -tolerated plaque assessment technique with high temporal resolution, albeit tempered by relatively low spatial resolution.
Nontargeted microbubbles
Nontargeted ultrasound contrast agents composed of gas-filled protein, lipid or biopolymer microbubbles confined to the blood pool can identify plaque neovessels. When excited, high-frequency microbubble size oscillations produce a unique acoustic signal for optimized detection. In 13 patients with carotid atheroma, quantitative nontargeted microbubble contrast enhancement correlated well with FDG plaque inflammation from a nonconcurrent scan within 3 months (R ¼ 0. 
Targeted microbubbles
To probe plaque disease beyond structure, microbubble may be labelled with an antibody or small molecule that reports on a biologically relevant process. In hypercholesterolemic primates imaged serially every 4 months for 2 years, P-selectin and vascular cell adhesion molecule 1 (VCAM-1)targeted microbubble identified carotid artery endothelial activation (five-to seven-fold enhanced microbubble attachment) that was in proportion to the duration of insulin resistance and prior to ultrasound-detectable plaque formation [35 & ]. Further preclinical evidence suggests that VCAM-1-targeted microbubble can serially monitor endothelial damage recovery, such as occurs after percutaneous intervention [36 & ].
OPTICAL IMAGING
Optical coherence tomography
Light-based imaging strategies are gaining hold in clinical use due to their safety, speed and capacity for high-resolution plaque imaging. Intravascular optical coherence tomography (OCT) is the mainstay of current clinical optical imaging platforms, generating unsurpassed 10-20 mm resolution images of plaque structural constituents such as thrombus, thin fibrous caps, macrophages and neovessels during rapid, automated catheter pullback at rates of 40 mm/s or less. In 40 patients with mild coronary disease, OCT-identified coronary plaque macrophage accumulations and vasa vasorum neovessels correlated positively with endothelial dysfunction, defined as acetylcholine-induced 
Near-infrared fluorescence
Near-infrared fluorescence (NIRF) is an evolving translational optical imaging approach utilizing targets labelled with near-infrared fluorophores [40] . NIRF is quantitative and sensitive, and can be performed through blood without flushing with excellent signal-to-noise due to the low tissue autofluorescence present at near-infrared wavelengths. In preclinical studies, NIRF imaging of atheroma inflammation with protease or macrophagetargeted agents has demonstrated translational potential to detect high-risk plaque features. Building upon prior work [41, 42] , a high-speed intravascular NIRF-OCT catheter for combined molecular and structural plaque imaging was recently tested in rabbit atheroma to detect plaque inflammation using indocyanine green, a US Food and Drug Administration (FDA)-approved NIRF reporter 
CONCLUSION
Atherosclerosis continues to be a major cause of death and disability globally despite significant advances in detection and treatment. Although structural imaging has substantially enabled this growth, new biological molecular imaging approaches will improve our understanding of atherosclerosis pathobiology and offer venues to pursue new targeted therapeutic strategies. Inflammation and neovascularization, two key high-risk atheroma features, are being investigated in vivo via an expansion of imaging strategies and are being harnessed as imaging endpoints in trials testing novel antiatherosclerosis treatments. Future studies will aim to demonstrate the benefit of combined molecular and structural plaque imaging in predicting adverse cardiovascular outcomes. Overall, atherosclerosis plaque imaging is growing rapidly and possesses an exciting outlook to allow molecular detection of atherosclerosis, enable personalized therapy in patients with established disease and improve current paradigms for cardiovascular disease treatment.
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